Takeda completed the acquisition of PvP Biologics.

Takeda Pharmaceutical, a pharmaceutical and biopharmaceutical company, completed the acquisition of PvP Biologics, a pharmaceutical company. Financial terms were not disclosed. “Takeda has been a great partner and has the expertise, resources, and commitment to people living with celiac disease required to lead the next stage of TAK-062 development,” Adam Simpson, PvP Biologics President, and CEO.